CLLS Cellectis S.A. IFRS
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1627281 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 · USD | FY20242024-12-31 · USD |
|---|---|---|
| Income statement | ||
| Revenue | $72.95M | $41.51M |
| Cost of revenue | $0 | $0 |
| Gross profit | $72.95M | $41.51M |
| R&D expense | $93.52M | $90.54M |
| SG&A expense | $19.79M | $19.09M |
| Operating income | -$33.08M | -$59.55M |
| Interest expense | $51.06M | $21.61M |
| Pretax income | -$68.02M | -$36.76M |
| Income tax | -$423,000 | $0 |
| Net income | -$67.59M | -$36.76M |
| EBITDA | -$13.01M | -$39.71M |
| EPS (basic) | -0.67 | -0.41 |
| EPS (diluted) | -0.67 | -0.41 |
| Weighted avg. shares (diluted) | 100.28M | 90.57M |
| Balance sheet | ||
| Cash & equivalents | $61.53M | $143.25M |
| Short-term investments | $144.80M | $115.80M |
| Receivables | $14.40M | $6.71M |
| PP&E, netmay include right-of-use assets (IFRS) | $38.79M | $45.90M |
| Intangibles | $535,000 | $1.12M |
| Total assets | $324.72M | $383.54M |
| Current liabilities | $145.75M | $166.27M |
| Total liabilities | $248.82M | $252.51M |
| Shareholders' equity | $75.90M | $131.03M |
| Shares outstanding | 100.34M | 100.09M |
| Cash flow statement | ||
| Operating cash flow | -$39.40M | $22.99M |
| Capital expenditure | $2.36M | $2.58M |
| Free cash flow | -$41.76M | $20.41M |
| Investing cash flow | -$29.48M | -$102.81M |
| Financing cash flow | -$16.76M | $89.11M |
| Depreciation & amortization | $20.06M | $19.85M |
| Stock-based compensation | $6.11M | $3.17M |
Free plan shows the latest 2 periods; Pro shows all 12 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.